GlassScriptPhysician profile
Marina A Valdes
NPI 1912247487
$23,487.52
in general payments reported to CMS, 2019-2025
32 companies · $5,036 in 2025
The $5,036 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,684 · 2022: $4,295 · 2023: $4,539 · 2024: $5,934 · 2025: $5,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,508.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,637.69 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,725.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,055.91 | 2021-2025 | |
| Janssen Biotech, INC. | $1,644.62 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $1,547.20 | 2021-2025 | Saphnelo, Evusheld, Flumist Quadrivalent |
| Pfizer INC. | $1,241.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,168.33 | 2021-2025 | Benlysta, Nucala |
| Ucb, INC. | $1,145.04 | 2021-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $1,017.26 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $890.40 | 2021-2025 | Acthar |
| Lilly USA, LLC | $869.99 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Janssen Scientific Affairs, LLC | $545.77 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $464.31 | 2021-2025 | Orencia |
| Horizon Therapeutics Plc | $379.46 | 2021-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $319.00 | 2023-2025 | Idacio, Tyenne |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $314.55 | 2021-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $307.90 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Genentech USA, INC. | $296.91 | 2023-2025 | Actemra, Gazyva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.06 | 2021-2024 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $119.32 | 2024-2025 | Lupkynis |
| Sandoz INC. | $104.44 | 2024-2025 | Jubbonti, Hyrimoz |
| Alexion Pharmaceuticals, INC. | $97.48 | 2021-2025 | Strensiq |
| Alkermes, INC. | $85.73 | 2022 | |
| Scilex Pharmaceuticals INC. | $47.91 | 2024 | |
| Organon LLC | $47.78 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $46.47 | 2023-2024 | Crysvita, Crysvita |
| Sobi, INC | $42.56 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $41.45 | 2024 | Arcalyst |
| Tersera Therapeutics LLC | $41.32 | 2025 | Quzyttir |
| Kiniksa Pharmaceuticals, LTD. | $31.52 | 2023 | Arcalyst |
| Fidia Pharma USA INC. | $16.25 | 2021 | |
| Hikma Pharmaceuticals USA | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.